# Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL

> **NCT00854568** · PHASE3 · COMPLETED · sponsor: **Fudan University** · enrollment: 398 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** CEOP regimen
- **DRUG:** CHOP regimen

## Key facts

- **NCT ID:** NCT00854568
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-12
- **Final completion:** 2013-02
- **Target enrollment:** 398 (ACTUAL)
- **Last updated:** 2014-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854568, "Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00854568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*